RT Journal Article
SR Electronic
T1 Dynamics of IgG seroconversion and pathophysiology of COVID-19 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.07.20124636
DO 10.1101/2020.06.07.20124636
A1 Henry M Staines
A1 Daniela E Kirwan
A1 David J Clark
A1 Emily R Adams
A1 Yolanda Augustin
A1 Rachel L Byrne
A1 Michael Cocozza
A1 Ana I Cubas-Atienzar
A1 Luis E. Cuevas
A1 Martina Cusinato
A1 Benedict M O Davies
A1 Mark Davis
A1 Paul Davis
A1 Annelyse Duvoix
A1 Nicholas M Eckersley
A1 Daniel Forton
A1 Alice J Fraser
A1 Gala Garrod
A1 Linda Hadcocks
A1 Qinxue Hu
A1 Michael Johnson
A1 Grant A Kay
A1 Kesja Klekotko
A1 Zawditu Lewis
A1 Derek C Macallan
A1 Josephine Mensah-Kane
A1 Stefanie Menzies
A1 Irene Monahan
A1 Catherine M Moore
A1 Gerhard Nebe-von-Caron
A1 Sophie I Owen
A1 Chris Sainter
A1 Amadou A Sall
A1 James Schouten
A1 Chris Williams
A1 John Wilkins
A1 Kevin Woolston
A1 Joseph R A Fitchett
A1 Sanjeev Krishna
A1 Tim Planche
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.07.20124636.1.abstract
AB We report dynamics of seroconversion to SARS-CoV-2 infections detected by IgG ELISA in 177 individuals diagnosed by RT-PCR. Longitudinal analysis identifies 2-8.5% of individuals who do not seroconvert even weeks after infection. They are younger than seroconverters who have increased co-morbidity and higher inflammatory markers such as C-Reactive Protein. Higher antibody responses are associated with non-white ethnicity. Antibody responses do not decline during follow up almost to 2 months. Serological assays increase understanding of disease severity. Their application in regular surveillance will clarify the duration and protective nature of humoral responses to SARS-CoV-2.Competing Interest StatementSK is a member of the Scientific Advisory Committee for the Foundation for Innovative New Diagnostics (FIND) a not-for-profit organisation that produces global guidance on affordable diagnostics. The views expressed here are personal opinions and do not represent the recommendations of FIND. Clinical TrialCclinicaltrials.gov NCT04351646. Funding StatementThis study was supported by a DFID/Wellcome Trust Epidemic Preparedness coronavirus grant (220764/Z/20/Z) to JRAF, SK, HMS, ERA, LEC. HMS is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St Georges University of London. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board ethical approval (DARTS study - IRAS project ID: 282104; REC reference: 20/SC/0171).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary data for methods and results referred to in the manuscript is submitted together with the manuscript.